Literature DB >> 23467510

Use of thiopurines in inflammatory bowel disease.

Pascal Frei1, Luc Biedermann, Ole Haagen Nielsen, Gerhard Rogler.   

Abstract

The use of thiopurines as immunosuppression for the treatment of refractory or chronic active inflammatory bowel disease is established for both Crohn's disease and ulcerative colitis. Nevertheless, many questions remain concerning the optimal treatment regimens of azathioprine, 6-mercaptopurine and thioguanine. We will briefly summarize dose recommendations, indications for thiopurine therapy and side effects which are relevant in clinical practice. We discuss some currently debated topics, including the combination of azathioprine and allopurinol, switching of thiopurine therapy in case of side effects, the use of azathioprine in pregnancy, the infection risk using thiopurines and the evidence when to stop thiopurines. Excellent reviews have been published on the thiopurine metabolic pathway which will not be discussed here in detail.

Entities:  

Keywords:  Crohn’s disease; Immunosuppression; Infection; Inflammatory bowel disease; Thiopurines; Ulcerative colitis

Mesh:

Substances:

Year:  2013        PMID: 23467510      PMCID: PMC3581991          DOI: 10.3748/wjg.v19.i7.1040

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  95 in total

1.  Role of azathioprine in severe ulcerative colitis: one-year, placebo-controlled, randomized trial.

Authors:  A Sood; V Midha; N Sood; V Kaushal
Journal:  Indian J Gastroenterol       Date:  2000 Jan-Mar

Review 2.  Dosing 6-thioguanine in inflammatory bowel disease: expert-based guidelines for daily practice.

Authors:  Margien L Seinen; Dirk P van Asseldonk; Chris J J Mulder; Nanne K H de Boer
Journal:  J Gastrointestin Liver Dis       Date:  2010-09       Impact factor: 2.008

3.  The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management.

Authors:  A Dignass; G Van Assche; J O Lindsay; M Lémann; J Söderholm; J F Colombel; S Danese; A D'Hoore; M Gassull; F Gomollón; D W Hommes; P Michetti; C O'Morain; T Oresland; A Windsor; E F Stange; S P L Travis
Journal:  J Crohns Colitis       Date:  2010-01-15       Impact factor: 9.071

4.  Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine.

Authors:  A Kandiel; A G Fraser; B I Korelitz; C Brensinger; J D Lewis
Journal:  Gut       Date:  2005-08       Impact factor: 23.059

5.  Toxicity of 6-thioguanine: no hepatotoxicity in a series of IBD patients treated with long-term, low dose 6-thioguanine. Some evidence for dose or metabolite level dependent effects?

Authors:  L P L Gilissen; L J J Derijks; A Driessen; L P Bos; P M Hooymans; R W Stockbrügger; L G J B Engels
Journal:  Dig Liver Dis       Date:  2006-12-26       Impact factor: 4.088

6.  Randomised controlled trial of azathioprine withdrawal in ulcerative colitis.

Authors:  A B Hawthorne; R F Logan; C J Hawkey; P N Foster; A T Axon; E T Swarbrick; B B Scott; J E Lennard-Jones
Journal:  BMJ       Date:  1992-07-04

7.  Azathioprine in ulcerative colitis: final report on controlled therapeutic trial.

Authors:  D P Jewell; S C Truelove
Journal:  Br Med J       Date:  1974-12-14

8.  Azathioprine treatment during lactation.

Authors:  L A Christensen; J F Dahlerup; M J Nielsen; J F Fallingborg; K Schmiegelow
Journal:  Aliment Pharmacol Ther       Date:  2008-08-30       Impact factor: 8.171

9.  Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease.

Authors:  W R Connell; M A Kamm; M Dickson; A M Balkwill; J K Ritchie; J E Lennard-Jones
Journal:  Lancet       Date:  1994-05-21       Impact factor: 79.321

10.  Postoperative maintenance of Crohn's disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial.

Authors:  Stephen B Hanauer; Burton I Korelitz; Paul Rutgeerts; Mark A Peppercorn; Ronald A Thisted; Russell D Cohen; Daniel H Present
Journal:  Gastroenterology       Date:  2004-09       Impact factor: 22.682

View more
  11 in total

1.  Redox cycling of Cu(II) by 6-mercaptopurine leads to ROS generation and DNA breakage: possible mechanism of anticancer activity.

Authors:  Sayeed Ur Rehman; Haseeb Zubair; Tarique Sarwar; Mohammed Amir Husain; Hassan Mubarak Ishqi; Shamshun Nehar; Mohammad Tabish
Journal:  Tumour Biol       Date:  2014-10-25

Review 2.  Thiopurines and Methotrexate Use in IBD Patients in a Biologic Era.

Authors:  Gerassimos J Mantzaris
Journal:  Curr Treat Options Gastroenterol       Date:  2017-03

3.  Azathioprine does not reduce adenoma formation in a mouse model of sporadic intestinal tumorigenesis.

Authors:  Mattheus C B Wielenga; Jooske F van Lidth de Jeude; Sanne L Rosekrans; Alon D Levin; Monique Schukking; Geert R A M D'Haens; Jarom Heijmans; Marnix Jansen; Vanesa Muncan; Gijs R van den Brink
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

4.  Thiopurine S-methyltransferase genetic polymorphisms in adult patients with inflammatory bowel diseases in the Latvian population.

Authors:  Polina Zalizko; Juris Stefanovics; Jelizaveta Sokolovska; Natalia Paramonova; Evija Klavina; Renars Erts; Vita Rovite; Janis Klovins; Aldis Pukitis
Journal:  Therap Adv Gastroenterol       Date:  2020-07-14       Impact factor: 4.409

5.  Chronic pancreatitis as presentation of Crohn's disease in a child.

Authors:  Daniela Knafelz; Fabio Panetta; Lidia Monti; Fiammetta Bracci; Bronislava Papadatou; Giuliano Torre; Luigi Dall'Oglio; Antonella Diamanti
Journal:  World J Gastroenterol       Date:  2013-08-21       Impact factor: 5.742

Review 6.  Thiopurine Therapy in Patients With Inflammatory Bowel Disease: A Focus on Metabolism and Pharmacogenetics.

Authors:  Ji Young Chang; Jae Hee Cheon
Journal:  Dig Dis Sci       Date:  2019-07-09       Impact factor: 3.487

Review 7.  Nucleoside transporter proteins as biomarkers of drug responsiveness and drug targets.

Authors:  Marçal Pastor-Anglada; Sandra Pérez-Torras
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

Review 8.  Therapeutic drug monitoring in inflammatory bowel disease.

Authors:  Uri Kopylov; Shomron Ben-Horin; Ernest Seidman
Journal:  Ann Gastroenterol       Date:  2014

Review 9.  How I treat my inflammatory bowel disease-patients with thiopurines?

Authors:  Berrie Meijer; Chris Jj Mulder; Adriaan A van Bodegraven; Nanne K H de Boer
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-11-06

10.  The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease.

Authors:  Marius Vögelin; Luc Biedermann; Pascal Frei; Stephan R Vavricka; Sylvie Scharl; Jonas Zeitz; Michael C Sulz; Michael Fried; Gerhard Rogler; Michael Scharl
Journal:  PLoS One       Date:  2016-05-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.